Immunosuppressive therapy of proliferative glomerulonephritis in children.
D000293:Adolescent; D001323:Autoantibodies / Q000032:analysis; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D003165:Complement System Proteins / Q000032:analysis; D003404:Creatinine / Q000097:blood / Q000652:urine; D005260:Female; D005455:Fluorescent Antibody Technique; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007166:Immunosuppressive Agents; D007668:Kidney / Q000473:pathology; D007970:Leukopenia / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000150:complications; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use*; D011507:Proteinuria
D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D003165:Complement System Proteins; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone